{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:15:17Z","timestamp":1788362117554,"version":"build-2803163510"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This meta-analysis aims to compare the QoL, efficacy, and safety of once-weekly LAGH versus daily GH in children with short stature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science from inception to June 30, 2026, for studies comparing LAGH with daily GH in children with short stature. Outcomes of interest encompassed QoL, efficacy, and safety. Pooled analyses were conducted using a random-effects model. Treatment effects for continuous and dichotomous variables were expressed as weighted mean differences (WMDs) and risk ratios (RRs), respectively, each with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty studies (27 cohorts) comprising 3,287 patients were included. Available QoL data from two major trials indicated comparable improvements between treatment groups, with a trend toward greater clinical benefit in psychosocial domains observed for a higher dose of Somapacitan. Regarding efficacy, no statistically significant differences were found between groups for height velocity (WMD: 0.26; 95% CI: -0.07 to 0.58; P\u00a0=\u00a00.124), height standard deviation score (SDS) (WMD: 0.04; 95% CI: -0.03 to 0.10; P\u00a0=\u00a00.285), or the ratio of bone age to chronological age (BA\/CA) (WMD: 0.00; 95% CI: -0.01 to 0.01; P\u00a0=\u00a00.999). However, the LAGH group exhibited a significantly greater increase in insulin-like growth factor 1 (IGF-1) SDS compared to the daily GH group (WMD: 0.37; 95% CI: 0.13 to 0.62; P\u00a0=\u00a00.003). Subgroup analyses suggested that efficacy may be influenced by the specific LAGH formulation and baseline patient characteristics. The safety analysis revealed a comparable overall risk of adverse events between groups (RR: 1.02; 95% CI: 0.97 to 1.08; P\u00a0=\u00a00.468).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Once-weekly LAGH demonstrates comparable efficacy and a similar overall safety profile to daily GH in children with short stature. By reducing injection frequency, LAGH offers the potential to enhance treatment convenience and adherence, which may translate into improved QoL. Further long-term studies are warranted to confirm these findings and to investigate formulation-specific effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1907184","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:39:47Z","timestamp":1788359987000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Weekly long-acting growth hormone versus daily growth hormone therapy on quality of life, efficacy, and safety in children with short stature: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Fan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Bethune International Peace Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linying","family":"Xiu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Bethune International Peace Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Bethune International Peace Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Bethune International Peace Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Bethune International Peace Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000452150","article-title":"Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: Growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency","volume":"86","author":"Grimberg","year":"2016","journal-title":"Horm Res Paediatr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00539-5","article-title":"Advances in differential diagnosis and management of growth hormone deficiency in children","volume":"17","author":"Hage","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1210\/er.2013-1067","article-title":"Isolated growth hormone deficiency (GHD) in childhood and adolescence: Recent advances","volume":"35","author":"Alatzoglou","year":"2014","journal-title":"Endocr Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.720419","article-title":"Short and long-term effects of growth hormone in children and adolescents with GH deficiency","volume":"12","author":"Ranke","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/endocrines4010001","article-title":"Idiopathic short stature: What to expect from genomic investigations","volume":"4","author":"Andrade","year":"2023","journal-title":"Endocrines"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0167","article-title":"Approach to the growth hormone-deficient child during transition to adulthood","volume":"92","author":"Radovick","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09590-5","article-title":"The continuum between GH deficiency and GH insensitivity in children","volume":"22","author":"Savage","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"B8","article-title":"Growth hormone therapy in children and adults","volume":"59","author":"Krysiak","year":"2007","journal-title":"Pharmacol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000350251","article-title":"Understanding the growth hormone therapy adherence paradigm: A systematic review","volume":"79","author":"Fisher","year":"2013","journal-title":"Horm Res Paediatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2006.114249","article-title":"Monitoring of concordance in growth hormone therapy","volume":"93","author":"Kapoor","year":"2008","journal-title":"Arch Dis Child"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz149","article-title":"Long-acting growth hormone preparations - Current status and future considerations","volume":"105","author":"Miller","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.17458\/per.vol16.2018.lh.longactingghpreparation","article-title":"Long-acting growth hormone preparations in the treatment of children","volume":"16","author":"Lal","year":"2018","journal-title":"Pediatr Endocrinol Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad039","article-title":"Long-term pegylated GH for children with GH deficiency: A large, prospective, real-world study","volume":"108","author":"Hou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1991.260.1.e101","article-title":"Temporal structure of in vivo growth hormone secretory events in humans","volume":"260","author":"Hartman","year":"1991","journal-title":"Am J Physiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/med.0000000000000416","article-title":"The current state of long-acting growth hormone preparations for growth hormone therapy","volume":"25","author":"Yuen","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae834","article-title":"Long-acting growth hormone therapy in pediatric growth hormone deficiency: A consensus statement","volume":"110","author":"Maniatis","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.709936","article-title":"Human growth and growth hormone: From antiquity to the recominant age to the future","volume":"12","author":"Graber","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14248740","article-title":"Comparative efficacy and safety of once-weekly pegylated recombinant human growth hormone versus daily growth hormone therapy in children: A systematic review and meta-analysis","volume":"14","author":"Bin-Abbas","year":"2025","journal-title":"J Clin Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106805","article-title":"Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis","volume":"193","author":"Mameli","year":"2023","journal-title":"Pharmacol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7326\/m14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B22","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2009"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/0272989x05282643","article-title":"The interpretation of random-effects meta-analysis in decision models","volume":"25","author":"Ades","year":"2005","journal-title":"Med Decis Making"},{"key":"B25","doi-asserted-by":"crossref","first-page":"chap 9","DOI":"10.1002\/9780470712184.ch9","article-title":"Analyzing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions 5.0.1","author":"Deeks","year":"2008"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B27","article-title":"Assessing the influence of a single study in meta-analysis","volume":"47","author":"Tobias","year":"1999","journal-title":"Stata Tech Bull"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: The difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4020-8486-7_10","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2234","article-title":"Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD)","volume":"97","author":"P\u00e9ter","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1530\/eje-13-0148","article-title":"Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency","volume":"169","author":"Hwang","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2502","article-title":"24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency","volume":"99","author":"Khadilkar","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/eje-16-0905","article-title":"Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: Phase II and phase III multicenter, randomized studies","volume":"177","author":"Luo","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3776","article-title":"A randomized phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency","volume":"102","author":"Chatelain","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3547","article-title":"Long-acting C-terminal peptide-modified hGH (MOD-4023): Results of a safety and dose-finding study in GHD children","volume":"102","author":"Zelinska","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000489262","article-title":"Once-weekly administration of sustained-release growth hormone in Korean prepubertal children with idiopathic short stature: A randomized, controlled phase II study","volume":"90","author":"Hwang","year":"2018","journal-title":"Horm Res Paediatr"},{"key":"B39","article-title":"12-month effects of once-weekly and twice-monthly administration of hybrid Fc-fused human growth hormone, GX-H9, treatment in pediatric with GHD deficiency","volume":"90","author":"Malieyskiy","year":"2018","journal-title":"Horm Res Paediatr"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1438723","article-title":"Use of PEGylated recombinant human growth hormone in Chinese children with growth hormone deficiency: A 24-month follow-up study","volume":"2019","author":"Qiao","year":"2019","journal-title":"Int J Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz310","article-title":"Once-weekly somapacitan vs daily GH in children with GH deficiency: Results from a randomized phase 2 trial","volume":"105","author":"S\u00e4vendahl","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa046.603","article-title":"First report of disease-specific patient reported outcomes from a randomized phase 2 trial of once-weekly somapacitan versus daily GH in children with GHD","volume":"93","author":"Brod","year":"2020","journal-title":"Horm Res Paediatr"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.779365","article-title":"Reduced effectiveness and comparable safety in biweekly vs. weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency: A phase IV non-inferiority threshold targeted trial","volume":"12","author":"Sun","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1530\/ey.19.4.8","article-title":"Weekly lonapegsomatropin in treatment-na\u00efve children with growth hormone deficiency: The phase 3 heiGHt trial","volume":"106","author":"Thornton","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","first-page":"755","article-title":"Study on the efficacy and safety of long-acting growth hormones in treating pediatric growth hormone deficiency patients","volume":"29","author":"Wan","year":"2021","journal-title":"Chin J Child Health Care"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1530\/ey.20.2.8","article-title":"Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: A phase 3 study","volume":"107","author":"Deal","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","first-page":"S506","DOI":"10.1016\/j.jval.2020.08.601","article-title":"Evaluation of quality of life in pre-pubertal children using the quality of life in short stature youth (qolissy) questionnaire, following 12 months of growth hormone treatment with either a weekly somatrogon or a daily genotropin injection schedule","volume":"23","author":"Loftus","year":"2020","journal-title":"Value Health"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2290623","article-title":"Health-related quality of life in pre-pubertal children with pediatric growth hormone deficiency: 12-month results from a phase 3 clinical trial of once-weekly somatrogon versus once-daily somatropin","volume":"40","author":"Loftus","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1159\/000524600","article-title":"Efficacy and safety of once-weekly somatrogon compared with once-daily somatropin (Genotropin\u00ae) in Japanese children with pediatric growth hormone deficiency: Results from a randomized phase 3 study","volume":"95","author":"Horikawa","year":"2022","journal-title":"Horm Res Paediatr"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2021-0735","article-title":"Evaluation of efficacy and safety of long-acting PEGylated recombinant human growth hormone (Jintrolong) for patients with growth hormone deficiency","volume":"35","author":"Du","year":"2022","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1055\/a-1842-0724","article-title":"First clinical study on long-acting growth hormone therapy in children with Turner sydrome","volume":"54","author":"Gao","year":"2022","journal-title":"Horm Metab Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/cen.15025","article-title":"Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial","volume":"100","author":"Mori","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-024-05719-9","article-title":"Effect of long-acting PEGylated growth hormone for catch-up growth in children with idiopathic short stature: a 2-year real-world retrospective cohort study","volume":"183","author":"Xie","year":"2024","journal-title":"Eur J Pediatr"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae816","article-title":"A novel Y-shaped pegylated recombinant human growth hormone for children with growth hormone deficiency","volume":"110","author":"Liang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000545786","article-title":"Somapacitan is effective and well tolerated in Chinese children with growth hormone deficiency: A randomized controlled phase 3 study","volume":"5","author":"Fu","year":"2025","journal-title":"Horm Res Paediatr"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/17520363.2025.2587570","article-title":"Efficacy of different measures of long-acting growth hormone in treating children with short stature","volume":"19","author":"Cai","year":"2025","journal-title":"biomark Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvag027","article-title":"Somapacitan in children with idiopathic short stature: a randomized controlled phase 3 study","volume":"194","author":"Abuzzahab","year":"2026","journal-title":"Eur J Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000550980","article-title":"Once-weekly lonapegsomatropin was efficacious and well tolerated in Chinese children with growth hormone deficiency: Results from a phase 3 randomized trial","volume":"27","author":"Ying","year":"2026","journal-title":"Horm Res Paediatr"},{"key":"B59","doi-asserted-by":"publisher","first-page":"146","DOI":"10.21037\/tp-2025-1-935","article-title":"Weekly pegylated recombinant human growth hormone for prepubertal children with growth hormone deficiency: adherence advantage drives superior short-term efficacy over daily rhGH","volume":"15","author":"Guo","year":"2026","journal-title":"Transl Pediatr"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000552183","article-title":"Extension of the phase 3 trial of somatrogon in children with growth hormone deficiency: 3 years of safety and efficacy","volume":"1","author":"Stawerska","year":"2026","journal-title":"Horm Res Paediatr"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2026.101714","article-title":"Real world performance of once weekly somatrogon on naive patients with isolated growth hormone deficiency: Mind the weight gain","volume":"85","author":"Moutafi","year":"2026","journal-title":"Growth Hormone IGF Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2026.03.096","article-title":"Comparative efficacy and safety of Jintrolong and other long-acting growth hormones for growth hormone deficiency in East Asia: A systematic review and network meta-analysis","volume":"1","author":"Liu","year":"2026","journal-title":"Endocr Pract"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgag093","article-title":"Long-acting growth hormone for treating growth hormone deficiency in children: a meta-analysis of randomized controlled trials focusing on changes in body mass index","volume":"111","author":"Levaillant","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1818944","article-title":"Treatment with long-acting growth hormone: effectiveness and safety","volume":"17","author":"Basile","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1159\/000490115","article-title":"Long-acting growth hormone in idiopathic short stature","volume":"90","author":"Saenger","year":"2018","journal-title":"Horm Res Paediatr"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-05239-y","article-title":"Novel therapies for growth disorders","volume":"183","author":"Galetaki","year":"2024","journal-title":"Eur J Pediatr"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1159\/000523791","article-title":"Long-acting growth hormone preparations and their use in children with growth hormone deficiency","volume":"96","author":"Pampanini","year":"2023","journal-title":"Horm Res Paediatr"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1530\/erc-22-0400","article-title":"The science behind the relations among cancer, height, growth patterns, and growth hormone axis","volume":"30","author":"Boguszewski","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20233","article-title":"IGF-I and breast cancer: a meta-analysis","volume":"111","author":"Shi","year":"2004","journal-title":"Int J Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24927","article-title":"Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies","volume":"126","author":"Rinaldi","year":"2010","journal-title":"Int J Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-15-1551","article-title":"A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk","volume":"76","author":"Travis","year":"2016","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1530\/ey.19.9.1","article-title":"Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement","volume":"186","author":"Boguszewski","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.26402\/jpp.2018.2.08","article-title":"Evaluation of glucose metabolism in children with growth hormone deficiency during long-term growth hormone treatment","volume":"69","author":"Witkowska-Sedek","year":"2018","journal-title":"J Physiol Pharmacol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1907184\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:39:51Z","timestamp":1788359991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1907184\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":73,"alternative-id":["10.3389\/fendo.2026.1907184"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1907184","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"article-number":"1907184"}}